Is STIM or RNXT more profitable?

Neuronetics has a net margin of -19.62% compared to RenovoRx's net margin of -621.71%. Neuronetics' return on equity of -125.11% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets Neuronetics -19.62% -125.11% -22.15% RenovoRx -621.71% -135.11% -101.91%

Does the media favor STIM or RNXT?

In the previous week, RenovoRx had 9 more articles in the media than Neuronetics. MarketBeat recorded 10 mentions for RenovoRx and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat RenovoRx's score of 0.86 indicating that Neuronetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neuronetics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive RenovoRx 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, RNXT or PDEX?

Pro-Dex has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio RenovoRx $1.98M 57.55 -$11.17M -$0.31 N/A Pro-Dex $66.59M 3.00 $8.98M $3.62 17.29

Is RNXT or PDEX more profitable?

Pro-Dex has a net margin of 16.08% compared to RenovoRx's net margin of -621.71%. Pro-Dex's return on equity of 22.78% beat RenovoRx's return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -621.71% -135.11% -101.91% Pro-Dex 16.08% 22.78% 14.30%

Does the media favor CNXU or RNXT?

In the previous week, RenovoRx had 8 more articles in the media than Conexeu Sciences. MarketBeat recorded 10 mentions for RenovoRx and 2 mentions for Conexeu Sciences. RenovoRx's average media sentiment score of 0.86 beat Conexeu Sciences' score of 0.80 indicating that RenovoRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Conexeu Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RenovoRx 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is RNXT or FOCL more profitable?

FocalTherics has a net margin of -56.26% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat FocalTherics' return on equity. Company Net Margins Return on Equity Return on Assets RenovoRx -621.71% -135.11% -101.91% FocalTherics -56.26% -248.00% -44.69%

Does the media prefer RNXT or FOCL?

In the previous week, FocalTherics had 3 more articles in the media than RenovoRx. MarketBeat recorded 13 mentions for FocalTherics and 10 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.86 beat FocalTherics' score of 0.72 indicating that RenovoRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RenovoRx 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive FocalTherics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, OWLT or RNXT?

RenovoRx has lower revenue, but higher earnings than Owlet. RenovoRx is trading at a lower price-to-earnings ratio than Owlet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Owlet $105.70M 1.40 -$39.68M -$0.75 N/A RenovoRx $1.98M 57.55 -$11.17M -$0.31 N/A

Is OWLT or RNXT more profitable?

Owlet has a net margin of -8.61% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Owlet's return on equity. Company Net Margins Return on Equity Return on Assets Owlet -8.61% -601.24% -15.96% RenovoRx -621.71% -135.11% -101.91%

RenovoRx (RNXT) Competitors

$2.52 +0.41 (+19.43%)

Closing price 09/2/2026 04:00 PM Eastern

Extended Trading

$2.78 +0.26 (+10.28%)

As of 04:50 AM Eastern

Compare

RNXT vs. STIM, PDEX, CNXU, FOCL, and OWLT

Should you buy RenovoRx stock or one of its competitors? RenovoRx's main competitors and comparable companies include Neuronetics (STIM), Pro-Dex (PDEX), Conexeu Sciences (CNXU), FocalTherics (FOCL), and Owlet (OWLT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does RenovoRx compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by insiders. Comparatively, 9.4% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, RenovoRx had 9 more articles in the media than Neuronetics. MarketBeat recorded 10 mentions for RenovoRx and 1 mentions for Neuronetics. Neuronetics' average media sentiment score of 1.85 beat RenovoRx's score of 0.86 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
RenovoRx	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RenovoRx has lower revenue, but higher earnings than Neuronetics. RenovoRx is trading at a lower price-to-earnings ratio than Neuronetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	1.42	-$39M	-$0.44	N/A
RenovoRx	$1.98M	57.55	-$11.17M	-$0.31	N/A

Neuronetics presently has a consensus target price of $4.50, indicating a potential upside of 62.45%. RenovoRx has a consensus target price of $8.50, indicating a potential upside of 237.30%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Neuronetics has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Neuronetics has a net margin of -19.62% compared to RenovoRx's net margin of -621.71%. Neuronetics' return on equity of -125.11% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-19.62%	-125.11%	-22.15%
RenovoRx	-621.71%	-135.11%	-101.91%

Summary

Neuronetics beats RenovoRx on 9 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Pro-Dex?

RenovoRx (NASDAQ:RNXT) and Pro-Dex (NASDAQ:PDEX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Pro-Dex has a net margin of 16.08% compared to RenovoRx's net margin of -621.71%. Pro-Dex's return on equity of 22.78% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-621.71%	-135.11%	-101.91%
Pro-Dex	16.08%	22.78%	14.30%

In the previous week, RenovoRx had 10 more articles in the media than Pro-Dex. MarketBeat recorded 10 mentions for RenovoRx and 0 mentions for Pro-Dex. RenovoRx's average media sentiment score of 0.86 beat Pro-Dex's score of 0.00 indicating that RenovoRx is being referred to more favorably in the media.

Company	Overall Sentiment
RenovoRx	Positive
Pro-Dex	Neutral

Pro-Dex has higher revenue and earnings than RenovoRx. RenovoRx is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.98M	57.55	-$11.17M	-$0.31	N/A
Pro-Dex	$66.59M	3.00	$8.98M	$3.62	17.29

RenovoRx currently has a consensus price target of $8.50, suggesting a potential upside of 237.30%. Pro-Dex has a consensus price target of $70.00, suggesting a potential upside of 11.86%. Given RenovoRx's stronger consensus rating and higher possible upside, research analysts plainly believe RenovoRx is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Pro-Dex	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Comparatively, 45.9% of Pro-Dex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

RenovoRx has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Pro-Dex has a beta of 0.06, meaning that its share price is 94% less volatile than the broader market.

Summary

Pro-Dex beats RenovoRx on 9 of the 17 factors compared between the two stocks.

How does RenovoRx compare to Conexeu Sciences?

Conexeu Sciences (NASDAQ:CNXU) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings and institutional ownership.

3.1% of RenovoRx shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Conexeu Sciences currently has a consensus price target of $20.00, indicating a potential upside of 259.71%. RenovoRx has a consensus price target of $8.50, indicating a potential upside of 237.30%. Given Conexeu Sciences' higher possible upside, equities research analysts clearly believe Conexeu Sciences is more favorable than RenovoRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

Conexeu Sciences has higher earnings, but lower revenue than RenovoRx. Conexeu Sciences is trading at a lower price-to-earnings ratio than RenovoRx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.11	N/A
RenovoRx	$1.98M	57.55	-$11.17M	-$0.31	N/A

Conexeu Sciences has a net margin of 0.00% compared to RenovoRx's net margin of -621.71%. Conexeu Sciences' return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Conexeu Sciences	N/A	N/A	N/A
RenovoRx	-621.71%	-135.11%	-101.91%

In the previous week, RenovoRx had 8 more articles in the media than Conexeu Sciences. MarketBeat recorded 10 mentions for RenovoRx and 2 mentions for Conexeu Sciences. RenovoRx's average media sentiment score of 0.86 beat Conexeu Sciences' score of 0.80 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Conexeu Sciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RenovoRx	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

RenovoRx beats Conexeu Sciences on 9 of the 15 factors compared between the two stocks.

How does RenovoRx compare to FocalTherics?

RenovoRx (NASDAQ:RNXT) and FocalTherics (NASDAQ:FOCL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

RenovoRx has higher earnings, but lower revenue than FocalTherics. RenovoRx is trading at a lower price-to-earnings ratio than FocalTherics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RenovoRx	$1.98M	57.55	-$11.17M	-$0.31	N/A
FocalTherics	$70.53M	2.25	-$29.25M	-$1.03	N/A

RenovoRx currently has a consensus target price of $8.50, suggesting a potential upside of 237.30%. FocalTherics has a consensus target price of $7.75, suggesting a potential upside of 83.65%. Given RenovoRx's stronger consensus rating and higher possible upside, equities research analysts clearly believe RenovoRx is more favorable than FocalTherics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
FocalTherics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

FocalTherics has a net margin of -56.26% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat FocalTherics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RenovoRx	-621.71%	-135.11%	-101.91%
FocalTherics	-56.26%	-248.00%	-44.69%

In the previous week, FocalTherics had 3 more articles in the media than RenovoRx. MarketBeat recorded 13 mentions for FocalTherics and 10 mentions for RenovoRx. RenovoRx's average media sentiment score of 0.86 beat FocalTherics' score of 0.72 indicating that RenovoRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RenovoRx	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
FocalTherics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

3.1% of RenovoRx shares are owned by institutional investors. Comparatively, 62.7% of FocalTherics shares are owned by institutional investors. 9.4% of RenovoRx shares are owned by company insiders. Comparatively, 10.1% of FocalTherics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

RenovoRx has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market. Comparatively, FocalTherics has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Summary

RenovoRx beats FocalTherics on 9 of the 16 factors compared between the two stocks.

How does RenovoRx compare to Owlet?

Owlet (NYSE:OWLT) and RenovoRx (NASDAQ:RNXT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

RenovoRx has lower revenue, but higher earnings than Owlet. RenovoRx is trading at a lower price-to-earnings ratio than Owlet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Owlet	$105.70M	1.40	-$39.68M	-$0.75	N/A
RenovoRx	$1.98M	57.55	-$11.17M	-$0.31	N/A

Owlet presently has a consensus price target of $15.00, indicating a potential upside of 195.28%. RenovoRx has a consensus price target of $8.50, indicating a potential upside of 237.30%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts clearly believe RenovoRx is more favorable than Owlet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

In the previous week, RenovoRx had 10 more articles in the media than Owlet. MarketBeat recorded 10 mentions for RenovoRx and 0 mentions for Owlet. Owlet's average media sentiment score of 1.84 beat RenovoRx's score of 0.86 indicating that Owlet is being referred to more favorably in the media.

Company	Overall Sentiment
Owlet	Very Positive
RenovoRx	Positive

Owlet has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Owlet has a net margin of -8.61% compared to RenovoRx's net margin of -621.71%. RenovoRx's return on equity of -135.11% beat Owlet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Owlet	-8.61%	-601.24%	-15.96%
RenovoRx	-621.71%	-135.11%	-101.91%

72.6% of Owlet shares are held by institutional investors. Comparatively, 3.1% of RenovoRx shares are held by institutional investors. 36.2% of Owlet shares are held by company insiders. Comparatively, 9.4% of RenovoRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Owlet beats RenovoRx on 9 of the 17 factors compared between the two stocks.

Get RenovoRx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNXT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNXT vs. The Competition

Export

Metric	RenovoRx	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$95.22M	$5.75B	$7.20B	$12.67B
Dividend Yield	N/A	1.76%	2.53%	8.56%
P/E Ratio	-8.13	25.86	272.67	25.23
Price / Sales	57.55	81.03	636.84	104.57
Price / Cash	N/A	33.05	76.98	52.08
Price / Book	12.60	6.08	12.97	6.10
Net Income	-$11.17M	$147.75M	$3.47B	$348.86M
7 Day Performance	70.27%	-0.76%	-0.11%	-1.90%
1 Month Performance	137.74%	3.75%	6.74%	1.96%
1 Year Performance	101.60%	7.36%	25.06%	15.30%

RenovoRx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNXT RenovoRx	2.7898 of 5 stars	$2.52 +19.4%	$8.50 +237.3%	+133.3%	$95.22M	$1.98M	N/A	6	Analyst Revision High Trading Volume
STIM Neuronetics	4.0147 of 5 stars	$2.98 +3.1%	$4.50 +51.0%	-11.8%	$220.21M	$149.16M	N/A	180	Positive News
PDEX Pro-Dex	1.4821 of 5 stars	$65.22 -2.5%	$70.00 +7.3%	+35.9%	$213.47M	$74.64M	18.02	140
CNXU Conexeu Sciences	3.5199 of 5 stars	$7.55 -3.3%	$20.00 +164.9%	N/A	$202.02M	N/A	N/A	4
FOCL FocalTherics	4.4345 of 5 stars	$4.39 +5.0%	$7.75 +76.5%	N/A	$156.87M	$70.53M	N/A	230

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNXT) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RenovoRx (RNXT) Competitors

RNXT vs. STIM, PDEX, CNXU, FOCL, and OWLT

How does RenovoRx compare to Neuronetics?

Summary

How does RenovoRx compare to Pro-Dex?

Summary

How does RenovoRx compare to Conexeu Sciences?

Summary

How does RenovoRx compare to FocalTherics?

Summary

How does RenovoRx compare to Owlet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RenovoRx (RNXT) Competitors

RNXT vs. STIM, PDEX, CNXU, FOCL, and OWLT

How does RenovoRx compare to Neuronetics?

Do insiders & institutionals believe in STIM or RNXT?

Does the media favor STIM or RNXT?

Which has preferable earnings and valuation, STIM or RNXT?

Do analysts recommend STIM or RNXT?

Which has more volatility & risk, STIM or RNXT?

Is STIM or RNXT more profitable?

Summary

How does RenovoRx compare to Pro-Dex?

Is RNXT or PDEX more profitable?

Does the media refer more to RNXT or PDEX?

Which has higher earnings & valuation, RNXT or PDEX?

Do analysts rate RNXT or PDEX?

Do insiders and institutionals hold more shares of RNXT or PDEX?

Which has more volatility & risk, RNXT or PDEX?

Summary

How does RenovoRx compare to Conexeu Sciences?

Do insiders & institutionals have more ownership in CNXU or RNXT?

Do analysts rate CNXU or RNXT?

Which has better earnings & valuation, CNXU or RNXT?

Is CNXU or RNXT more profitable?

Does the media favor CNXU or RNXT?

Summary

How does RenovoRx compare to FocalTherics?

Which has higher earnings & valuation, RNXT or FOCL?

Do analysts recommend RNXT or FOCL?

Is RNXT or FOCL more profitable?

Does the media prefer RNXT or FOCL?

Do insiders & institutionals hold more shares of RNXT or FOCL?

Which has more risk and volatility, RNXT or FOCL?

Summary

How does RenovoRx compare to Owlet?

Which has higher earnings and valuation, OWLT or RNXT?

Do analysts recommend OWLT or RNXT?

Does the media favor OWLT or RNXT?

Which has more volatility and risk, OWLT or RNXT?

Is OWLT or RNXT more profitable?

Do insiders and institutionals have more ownership in OWLT or RNXT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNXT vs. The Competition

RenovoRx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools